Naturhouse Health (NTH) AI Stock Analysis

Top Page

Naturhouse Health

(BME:NTH)

Select Model

Rating:71Outperform

Price Target:EUR 3.00▲(32.16% Upside)

Action:reiterated

Date:08/04/26

The score is driven primarily by solid financial quality—strong profitability, healthy cash generation, and historically conservative leverage—supported by an attractive dividend yield. These positives are tempered by the steep 2025 revenue decline and reduced equity base, while technicals add modest support with price trading above key moving averages and moderate momentum.

Positive Factors

High profitability and marginsConsistently high margins indicate a durable ability to generate operating profit per unit of revenue, supporting cash flow and dividend capacity even if top-line growth slows. Strong margin structure preserves operating leverage and allows the company to sustain profitability through cyclical pressures.

Negative Factors

Steep multi-year revenue declineA pronounced and persistent top-line contraction undermines scale economics for product sales and center profitability, threatening future margin sustainability and royalty/fee income. Continued revenue erosion can erode FCF and make it harder to maintain investment in the network or product development.

Naturhouse Health (NTH) vs. iShares MSCI Spain ETF (EWP)

Market Cap: EUR 136.09M
Dividend Yield: 13.22%
Average Volume (3M): 41.33K
Price to Earnings (P/E): 15.6
Beta (1Y): 0.27
Revenue Growth: -6.06%
EPS Growth: -15.89%
Country: Spain
Employees: 168
Sector: General
Sector Strength: 55
Industry: Packaged Foods

Naturhouse Health Business Overview & Revenue Model

Company Description

Naturhouse Health, S.A. is a prominent entity in the global nutrition and weight management sector, maintaining a significant presence across Spain, Italy, France, Poland, and numerous other international markets. The company provides a diverse array...

How the Company Makes Money

Naturhouse primarily makes money through (1) product sales and (2) network-related income tied to its branded centers. Product revenue is generated from selling dietetic and nutritional items (e.g., supplements and other weight-management/wellness pr...

Naturhouse Health Financial Statement Overview

Summary

Strong profitability and margins historically, with 2025 still highly profitable. Cash generation is solid with 2025 free cash flow improving despite lower revenue, and leverage has been conservative. The main drag is the multi-year revenue contraction, including a sharp -37.9% decline in 2025, plus a reduced 2025 equity/asset base that lowers the balance-sheet cushion.

Income Statement

62Positive

Balance Sheet

70Positive

Cash Flow

74Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	44.91M	47.63M	49.42M	50.41M	52.40M	57.59M
Gross Profit	31.84M	12.94M	35.46M	25.11M	37.48M	41.26M
EBITDA	11.11M	14.45M	15.63M	17.93M	15.61M	20.80M
Net Income	8.61M	10.09M	9.86M	11.29M	9.63M	13.36M
Balance Sheet
Total Assets	29.96M	33.43M	42.59M	48.85M	42.82M	49.00M
Cash, Cash Equivalents and Short-Term Investments	10.43M	14.57M	21.67M	27.10M	14.78M	27.25M
Total Debt	6.29M	3.43M	4.27M	5.05M	5.38M	4.37M
Total Liabilities	14.65M	15.68M	10.91M	18.21M	14.96M	12.92M
Stockholders Equity	15.31M	17.75M	31.68M	30.63M	27.81M	36.02M
Cash Flow
Free Cash Flow	10.74M	11.67M	11.22M	20.38M	6.13M	16.12M
Operating Cash Flow	10.61M	12.15M	11.56M	20.95M	7.10M	16.17M
Investing Cash Flow	423.00K	-420.00K	862.00K	-459.00K	-5.22M	-4.27M
Financing Cash Flow	-22.96M	-18.95M	-16.10M	-7.70M	-16.98M	-6.27M

Naturhouse Health Technical Analysis

Technical Analysis SentimentNeutral

Last Price2.27

Price Trends

50DMA2.35Negative

100DMA2.44Negative

200DMA2.46Negative

Market Momentum

MACD-0.02Negative

RSI50.17Neutral

STOCH39.68Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:NTH, the sentiment is Neutral. The current price of 2.27 is above the 20-day moving average (MA) of 2.20, below the 50-day MA of 2.35, and below the 200-day MA of 2.46, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.17 is Neutral, neither overbought nor oversold. The STOCH value of 39.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:NTH.

Naturhouse Health Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

ES:NTH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ES:EBRO	73Outperform	EUR 2.74B	12.26	9.51%	3.01%	-4.44%	13.17%
ES:PUIG	72Outperform	EUR 10.85B	18.52	14.66%	2.19%	3.63%	-10.79%
ES:NTH	71Outperform	EUR 136.09M	15.63	52.07%	13.22%	-6.06%	-15.89%
ES:DIA	58Neutral	EUR 2.63B	15.60	113.16%	―	2.05%	117.98%
ES:OLE	57Neutral	EUR 170.50M	9.32	8.23%	―	-15.27%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ES:PVA	38Underperform	EUR 6.35M	-49.11	2.00%	―	2.56%	-117.93%

* General Sector Average

Performance Comparison

ES:NTH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ES:NTH	Naturhouse Health	2.27	0.38	20.04%
ES:DIA	DISTRIBUIDORA INTERNACIONAL DE ALIMENTACION	45.40	17.20	60.99%
ES:EBRO	EBRO FOODS	17.78	0.65	3.82%
ES:PVA	Pescanova SA	0.22	-0.07	-24.05%
ES:OLE	DEOLEO S.A.	0.34	0.15	79.47%
ES:PUIG	Puig Brands, S.A.	19.26	4.74	32.61%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 04, 2026

Naturhouse Health AI Stock Analysis

Top Page